Stroke prevention in atrial fibrillation patients with chronic kidney disease

Canadian Journal of Cardiology

Volumn 29, Issue 7 SUPPL, 2013, Pages

  Hart, Robert G ^a   Eikelboom, John W ^a   Brimble, K Scott ^a   McMurtry, M Sean ^b   Ingram, Alistair J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; BRAIN EMBOLISM; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; DEHYDRATION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG USE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

EID: 84879543712     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.04.005     Document Type: Review

References (55)

1. Go A.S., Fang M.C., Udaltsova N., et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation. The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Circulation 2009, 199:1363-1369.
2. Kooiman J., van de Peppel W.R., van der Meer F.J., Huisman M.V. Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. JThromb Haemost 2011, 9:1652-1653.
3. Baber U., Howard V.J., Halperin J.L., et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol 2011, 4:26-32.
4. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(suppl 1):S1-266. National Kidney Foundation.
5. Soliman E.Z., Prineas R.J., Go A.S., et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010, 159:1102-1107.
6. Ananthapanyasut W., Napan S., Rudolph E.H., et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol 2010, 5:173-181.
7. McManus D.D., Corteville D.C., Shlipak M.G., Whooley M.A., Ix J.H. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol 2009, 104:1551-1555.
8. Sandhu R.K., Kurth T., Conen D., Cook N.R., Ridker P.M., Albert C.M. Relation of renal function to risk for incident atrial fibrillation in women. Am J Cardiol 2012, 109:538-542.
9. Alonso A., Lopez F.L., Matsushita K., et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011, 123:2946-2953.
10. Goldstein B.A., Arce C.M., Hlatky M.A., Turakhia M., Setoguchi S., Winkelmayer W.C. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation 2012, 126:2293-2301.
11. Knoll F., Sturm G., Lamina C., et al. Coumarins and survival in incident dialysis patients. Nephrol Dial Transplant 2012, 27:332-337.
12. Bansal N., Fan D., Hsu C.Y., Ordonez J.D., Marcus G.M., Go A.S. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 2013, 127:569-574.
13. Winkelmayer W.C. More evidence on an abominable pairing: atrial fibrillation and kidney disease. Circulation 2013, 127:560-562.
14. Eikelboom J.W., Connolly S.J., Gao P., et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. JStroke Cerebrovasc Dis 2012, 21:429-435.
15. Hart R.G., Pearce L.A., Asinger R.W., Herzog C.A. Stroke in atrial fibrillation patients with moderate chronic kidney disease: SPAF III Trials. Clin J Am Soc Nephrol 2011, 6:2599-2604.
16. Piccini J.P., Stevens S.R., Chang Y., et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Validation of the R2CHADS2 Index in the ROCKET-AF and ATRIA Study Cohorts. Circulation 2013, 127:224-232.
17. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
18. Herzog C.A., Asinger R.W., Berger A.K., et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011, 80:572-586.
19. Brimble K.S., Ingram A.J., Eikelboom J.W., Hart R.G. Anticoagulants in patients with atrial fibrillation with end-stage renal disease. Postgraduate Med 2012, 124:17-25.
20. Clase C.M., Holden R.M., Sood W.M., et al. Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation?. Nephrol Dialysis Transplant 2012, 27:3719-3724.
21. Shen J.I., Turakhia M.P., Winkelmayer W.C. Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks?. Curr Opin Nephrol Hypertens 2012, 21:600-606.
22. Nakagawa K., Hirai T., Takashima S., et al. Chronic kidney disease and CHADS2 score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am J Cardiol 2011, 107:912-916.
23. Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results of the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
24. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007, 69:546-554. Stroke Risk in Atrial Fibrillation Working Group.
25. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
26. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEngl J Med 2009, 361:1139-1151.
27. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. NEngl J Med 2011, 364:806-817.
28. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365:883-891.
29. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365:981-992.
30. Eikelboom J.W., Weitz J.I. New anticoagulants. Circulation 2010, 121:1523-1532.
31. Ruff C.T., Giugliano R.P., Antman E.M., et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation. Design and rationale for the Effective anticoagulation with factor Xa next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010, 160:635-641.
32. Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010, 49:259-268.
33. Kubitza D., Becka M., Mueck W., et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010, 70:703-712.
34. Hart R.G., Eikelboom J.W., Ingram A.J., Herzog C.A. Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nature Nephrol Rev 2012, 8:569-578.
35. Levey A.S., Stevens L.A., Schmid C.H., et al. Anew equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
36. Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights form the ARISTOTLE trial. Eur Heart J 2012, 33:2821-2830.
37. Eikelboom J.W., Wallentin L., Connolly S.J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. An analysis of the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY) Trial. Circulation 2011, 123:2363-2372.
38. Fox K.A., Piccini J.P., Wojdyla D., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011, 32:2387-2394.
39. Fang M.C., Go A.S., Chang Y., et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007, 120:700-705.
40. Hart R.G., Diener H.C., Yang S., et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012, 43:1511-1517.
41. Fang M.C., Go A.S., Chang Y., et al. Anew risk scheme to predict warfarin-associated hemorrhage. JAm Coll Cardiol 2011, 58:395-401.
42. Lehr T., Haertter S., Liesenfeld K.H., et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. JClin Pharmacol 2012, 52:1373-1378.
43. Genovesi S., Pogliani D., Faini A., et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis 2005, 46:897-902.
44. Wetmore J.B., Mahnken J.D., Rigler S.K., et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int 2012, 81:469-476.
45. Wizemann V., Tong L., Satayathum S., et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010, 77:1098-1106.
46. Genovesi S., Vincenti A., Rossi E., et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 2008, 51:255-262.
47. Winkelmayer W.C., Liu J., Setoguchi S., Choudry N.K. Effectiveness and safety of warfarin initiation in older hemodialysis patients with atrial fibrillation. Clin J Am Soc Nephrol 2011, 6:2662-2668.
48. Chan K.E., Lazarus J.M., Thadhani R., Hakim R.M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. JAm Soc Nephrol 2009, 20:2223-2233.
49. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 2005, 45S:S16-153.
50. Olesen J.B., Lip G.Y., Kamper A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. NEngl J Med 2012, 367:625-635.
51. Capodanno D., Angiolillo D.J. Antithrombotic therapy in patients with chronic kidney disease. Circulation 2012, 125:2649-2661.
52. Stevens L.A., Coresh J., Greene T., Levey A.S. Assessing kidney function-measured and estimated glomerular filtration rate. NEngl J Med 2006, 354:2473-2483.
53. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Rot D. Amore accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
54. Corsonello A., Pedone C., Lattanzio F., Onder G., Antonelli Incalzi R. Association between glomerular filtration rate and adverse drug reactions in elderly hospitalized patients: the role of the estimating equation. Drugs Aging 2011, 28:379-390. Gruppo Italiano di Farmacovigilanza nell'Anziano (GIFA).
55. Coresh J., Astor B.C., McQuillan G., et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002, 39:920-929.